GENFIT Logo

GENFIT

Develops therapies and diagnostics for patients with rare and severe liver diseases.

GNFT | PA

Overview

Corporate Details

ISIN(s):
FR0004163111 (+2 more)
LEI:
969500XPWN2DMZQA5X73
Country:
France
Address:
885 AVENUE EUGENE AVINEE, 59120 LOOS

Description

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-10 07:45
GENFIT signe un partenariat de recherche avec EVerZom pour faire progresser une…
French 204.9 KB
2025-11-10 07:45
GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Rege…
English 223.5 KB
2025-11-10 07:30
GENFIT présente de nouvelles données précliniques prometteuses sur NTZ/G1090N d…
French 315.9 KB
2025-11-10 07:30
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment …
English 217.0 KB
2025-09-22 22:00
Attestation de la personne responsable associée au rapport d'activité et financ…
French 118.9 KB
2025-06-17 20:30
GENFIT : Résultats de l’Assemblée Générale Mixte du 17 juin 2025
French 140.4 KB
2025-06-17 20:30
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
English 140.0 KB
2025-05-22 22:10
GENFIT Reports First Quarter 2025 Financial Information
English 163.4 KB
2025-05-22 22:10
GENFIT : Information financière du premier trimestre 2025
French 146.7 KB
2025-05-20 22:10
GENFIT to receive a €26.5 million milestone payment following the approval of p…
English 143.6 KB
2025-05-20 22:10
GENFIT va recevoir un paiement d’étape de 26,5 millions d’euros à la suite de l…
French 137.3 KB
2025-05-14 22:10
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year…
English 793.3 KB
2025-05-07 22:10
GENFIT : Assemblée Générale Mixte du 17 juin 2025 — modalités de mise à disposi…
French 129.1 KB
2025-05-07 22:10
GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Prepa…
English 135.6 KB
2025-05-05 07:30
GENFIT présentera ses dernières avancées dans l'ACLF à l’EASL Congress 2025
French 228.8 KB

Automate Your Workflow. Get a real-time feed of all GENFIT filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GENFIT

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GENFIT via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-07-07 N/A Other Buy 5,300 19,488.10 EUR
2023-07-06 N/A Other Buy 1,100 4,048.00 EUR
2023-07-05 N/A Other Buy 10,000 37,061.00 EUR
2023-07-03 N/A Other Buy 5,300 18,769.95 EUR

Peer Companies

Aptahem AB Logo
A clinical-stage biotech developing aptamer-based drugs for life-threatening conditions.
Sweden
APTA
APTAMER GROUP PLC Logo
Develops custom affinity binders for research, diagnostics, and therapeutics.
United Kingdom
APTA
Aptevo Therapeutics Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for cancer.
United States of America
APVO
Biotech firm providing MICROPIG models, bio-resources, and non-clinical CRO services.
South Korea
149300
Aran Research & Development (1982) Ltd. Logo
A product design and development firm providing services from concept to manufacturing.
Israel
ARAN
Artiva Biotherapeutics, Inc. Logo
Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.
United States of America
ARTV
ARVINAS, INC. Logo
Clinical-stage biopharma developing therapeutics based on targeted protein degradation.
United States of America
ARVN
Asarina Pharma AB Logo
A biotechnology company in liquidation, formerly focused on neurosteroid therapies.
Sweden
ASAP
Atara Biotherapeutics, Inc. Logo
Develops off-the-shelf allogeneic T-cell immunotherapies for cancer and autoimmune diseases.
United States of America
ATRA
An integrated biologics development partner offering services from DNA sequence to cell bank.
South Korea
355690

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.